FGF21 and metabolic dysfunction-associated steatohepatitis: Pegozafermin is a FGF21 analogue with a role in the treatment of MASH and hypertriglyceridemia: “Enliven” the double-blinded randomized phase 2b trial by Loomba et al. that established, among the primary endpoints, the improvements in fibrosis of at least 1 stage without MASH worsening.